PMC:7381711 / 793-1113
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T5 | 187-194 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T6 | 209-216 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
29 | 187-194 | Chemical | denotes | heparin | MESH:D006493 |
30 | 209-216 | Chemical | denotes | heparin | MESH:D006493 |
38 | 79-99 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
39 | 245-253 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T12 | 79-87 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T13 | 79-83 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T14 | 90-99 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T15 | 245-253 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T4 | 44-57 | Chemical | denotes | anticoagulant | http://purl.obolibrary.org/obo/CHEBI_50249 |
T5 | 187-194 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T6 | 209-216 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T7 | 222-227 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T8 | 262-271 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T9 | 101-302 | Sentence | denotes | Additionally, we review preclinical evidence establishing biological plausibility for heparin and synthetic heparin-like drugs as therapies for COVID-19 through antiviral and anti-inflammatory effects. |